Integrating analyses of genomics, longitudinal metabolomics, and Alzheimer’s risk factors in 1111 cohort participants revealed that changes in CSF metabolite levels explained more than 60% of variance in CSF levels of tau, a detrimental protein that accumulates in the brain of AD patients and is necessary for diagnosis [40]. This evidence concerns the gene MAPT and Alzheimer disease.